Pharmicell Co., Ltd., a prominent biopharmaceutical company based in Seoul, South Korea, has been making significant strides in the healthcare sector, particularly in the field of stem cell research and development. Founded in 1968, the company operates through two primary divisions: the Biopharmaceutical Business and the Biochemical Business. These divisions focus on developing and selling innovative stem cell drugs on a global scale.
One of the company’s flagship products, Cellgram-AMI, is manufactured using autologous bone marrow-derived mesenchymal stem cells. This product is specifically designed to enhance the ejection fraction in patients who have suffered an acute myocardial infarction and have undergone reperfusion via coronary angioplasty. This therapeutic approach highlights Pharmicell’s commitment to addressing critical cardiovascular conditions through advanced biotechnological solutions.
In addition to Cellgram-AMI, Pharmicell is actively developing a range of other products aimed at treating various medical conditions. These include Cellgram_IS and Cellgram_SCI, which are targeted at brain and nerve disorders; Cellgram_Lung, a drug for pulmonary diseases; Cellgram_LC, aimed at liver diseases; and Cellgram_ED and Cellgram_CLI, which are being developed for the treatment of graft-versus-host disease, kidney transplant complications, impotence, and critical lower limb ischemia. Furthermore, the company is working on dendritic cell products, such as Cellgram_DC, which is intended for cancer treatment.
Pharmicell’s Biochemical Business division complements its biopharmaceutical efforts by producing intermediates of raw material medicines, including nucleosides, mPEGs, and HDP-tosylates, as well as phosphorus-based flame retardants. This diversification underscores the company’s robust approach to leveraging biotechnology for a wide array of applications.
Beyond its core pharmaceutical products, Pharmicell has expanded its ventures into related fields. Twelve, a stem cell bank, and cell culture media cosmetics are among the company’s innovative projects, reflecting its broader vision of integrating stem cell technology into various aspects of healthcare and wellness.
As of November 2, 2026, Pharmicell’s stock was trading at a close price of 8,900 KRW on the Korea Exchange Stock Market. The company’s market capitalization stands at approximately 534 trillion KRW. Despite a challenging financial performance, as indicated by a price-to-earnings ratio of -23.93, Pharmicell’s strategic focus on cutting-edge research and development positions it as a key player in the biotechnology sector.
Throughout its history, Pharmicell has demonstrated a steadfast commitment to advancing healthcare through innovative stem cell therapies. With a diverse portfolio of products in development and a strong foundation in biotechnological research, the company continues to make significant contributions to the global healthcare landscape.
